Skip to main content

Additional Advances in HER2-Positive Metastatic Colorectal Cancer Research and Clinical Trials With Christopher Lieu, MD

Dr. Christopher Lieu, Associate Director of Clinical Research at the University of Colorado Cancer Center and Vice Chair of the National Comprehensive Cancer Network (NCCN), is currently serving as chair of i3 Health's online activity, live webinar, and meeting series, Hitting the Target in HER2-Positive Metastatic Colorectal Cancer. With numerous research advances occurring in this field during the past year, Dr. Lieu sat down with us again to share updates in targeted therapies for HER2-positive metastatic colorectal cancer and the evolving landscape of biomarkers under investigation for this disease.

Click the links below for Hitting the Target in HER2-Positive Metastatic Colorectal Cancer, an accredited CME/NCPD activity provided by i3 Health! 

Continue reading

Additional Advances in HER2-Positive Metastatic Colorectal Cancer Research and Clinical Trials With Christopher Lieu, MD

Dr. Christopher Lieu, Associate Director of Clinical Research at the University of Colorado Cancer Center and Vice Chair of the National Comprehensive Cancer Network (NCCN), is currently serving as chair of i3 Health's online activity, live webinar, and meeting series, Hitting the Target in HER2-Positive Metastatic Colorectal Cancer. With numerous research advances occurring in this field during the past year, Dr. Lieu sat down with us again to share updates in targeted therapies for HER2-positive metastatic colorectal cancer and the evolving landscape of biomarkers under investigation for this disease.

Click the links below for Hitting the Target in HER2-Positive Metastatic Colorectal Cancer, an accredited CME/NCPD activity provided by i3 Health!

Continue reading

Fighting Hereditary Colorectal Cancer Through Genetic Counseling With Catherine Skefos, MA, MS, CGC, and Julie Moskowitz, MS

In this edition of "Bridging the Gap in Cancer Care Through Genetic Counseling," Editorial Member Catherine Skefos speaks with her colleague Julie Moskowitz, MS, Genetic Counselor in the Gastrointestinal (GI) Center at MD Anderson Cancer Center, about hereditary aspects of colorectal cancer, how she counsels patients and families regarding their risk of colorectal cancer and related syndromes, and how genetic testing can be used to inform screening decisions and ultimately reduce patients' risk.  

Continue reading

Fighting Hereditary Colorectal Cancer Through Genetic Counseling With Catherine Skefos, MA, MS, CGC, and Julie Moskowitz, MS

In this edition of "Bridging the Gap in Cancer Care Through Genetic Counseling," Editorial Member Catherine Skefos speaks with her colleague Julie Moskowitz, MS, Genetic Counselor in the Gastrointestinal (GI) Center at MD Anderson Cancer Center, about hereditary aspects of colorectal cancer, how she counsels patients and families regarding their risk of colorectal cancer and related syndromes, and how genetic testing can be used to inform screening decisions and ultimately reduce patients' risk.  

Continue reading

Emerging Technologies in Therapeutics and Diagnostics

By Waqas Haque, MD, MPH

In this latest edition of The Way Ahead: The Convergence of Technology and Cancer Care, Dr. Waqas Haque shares his perspectives on the approval of lifileucel, the first individualized tumor-infiltrating lymphocyte therapy, for advanced melanoma; updates on the EV-302 trial of enfortumab vedotin, an antibody-drug conjugate technology; a new blood test for colorectal cancer screening from Guardant Health; the Model Facts label to guide decisions using machine learning; and more!  

Continue reading

Colorectal Cancer Awareness Month: Improving Research Through Advocacy With Allison Rosen, MS, and Matthew Hadfield, DO

In honor of Colorectal Cancer Awareness Month this March, Allison Rosen, MS, and Matthew Hadfield, DO, members of the OncData Editorial Board and Fellows Forum, sat down to discuss their perspectives on the month from both the clinical and survivorship viewpoints, including efforts to advocate for increased clinical trial funding, recent updates in research and treatment, and messages for both patients and the public about the importance of screening and raising awareness.  

Continue reading

Colorectal Cancer Awareness Month: Improving Research Through Advocacy With Allison Rosen, MS, and Matthew Hadfield, DO

In honor of Colorectal Cancer Awareness Month this March, Allison Rosen, MS, and Matthew Hadfield, DO, members of the OncData Editorial Board and Fellows Forum, sat down to discuss their perspectives on the month from both the clinical and survivorship viewpoints, including efforts to advocate for increased clinical trial funding, recent updates in research and treatment, and messages for both patients and the public about the importance of screening and raising awareness.  

Continue reading

National Cancer Prevention Month: Rising Trends and How to Combat Them With Samuel Kareff, Matthew Hadfield, Waqas Haque, and Joseph Kalis

In honor of National Cancer Prevention Month 2024, members of the Oncology Data Advisor Editorial Board and Fellows Forum sat down for a panel discussion about the rising incidence of cancer diagnoses, factors contributing to them, and how to counsel patients in light of these emerging trends.  

Continue reading

Exploring the Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer With Josep Tabernero, MD, PhD

At the recent American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.  

Continue reading

Exploring the Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer With Josep Tabernero, MD, PhD

At this weekend's American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.  

Continue reading

Fruquintinib Approved for Refractory Metastatic Colorectal Cancer

The FDA has approved fruquintinib (Fruzaqla™, Takeda Pharmaceuticals, Inc.) for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti–vascular endothelial growth factor (VEGF) therapy, and, if rat sarcoma (RAS) wild-type and medically appropriate, an anti–endothelial growth factor receptor (EGFR) therapy. This is the first approval of fruquintinib in the United States.   Why it matters: "There i...

Continue reading

Improved Understanding of Precision Medicine in BRAF V600E–Mutant Metastatic Colorectal Cancer

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding precision medicine in BRAF V600E­–mutant metastatic colorectal cancer (CRC).   Colorectal cancer is the second leading cause of cancer death among men and women in the United States, with the American Cancer Society estimating that there will be 106,970 new cases of colon cancer, 46,050 new cases of rectal cancer, and 52,550 deaths due to colorectal cancer in 2023 alon...

Continue reading

Tucatinib Plus Trastuzumab Approved for Colorectal Cancer

The FDA has granted accelerated approval to tucatinib (Tukysa®, Seagen, Inc.) with trastuzumab for rat sarcoma (RAS) wild-type human epidermal growth factor receptor 2 (HER2)–positive unresectable or metastatic colorectal cancer (CRC) that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. "Patients with chemotherapy-refractory HER2-positive metastatic colorectal cancer receive limited clinical benefit with currently available therapies," said John Stric...

Continue reading

Partnering With Patients Through Advocacy With Allison Rosen, MS

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Allison Rosen, a colorectal cancer survivor, patient advocate, and Director of Project ECHO for the American Cancer Society. Ms. Rosen shares the story of her cancer journey, how she became involved in patient advocacy, and how to strives to use her platform to bridge the gap between clinical research and cancer patients and survivors.  

Continue reading

Trifluridine and Tipiracil Plus Bevacizumab Approved for Previously Treated Metastatic Colorectal Cancer

The FDA has approved trifluridine and tipiracil (Lonsurf®, Taiho Oncology, Inc.) in combination with bevacizumab (Avastin®, Genentech, Inc.) for treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti–vascular endothelial growth factor (VEGF) biological therapy, and—if rat sarcoma (RAS) wild-type—an anti–epidermal growth factor receptor (EGFR) therapy. The FDA formerly a...

Continue reading

Cabozantinib/Atezolizumab and the Future of Metastatic Colorectal Cancer Treatment: Thomas Abrams, MD

Treatment options are limited for patients with metastatic colorectal cancer who have microsatellite-stable disease, which renders them ineligible for immune checkpoint inhibitor therapy. In a cohort of the COSMIC-021 trial, a team of researchers led by Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School, investigated the efficacy of cabozantinib plus atezolizumab for this patient population. Dr. Abrams recently presented the trial's results at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. In this interview, he discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.  

Continue reading

Cabozantinib/Atezolizumab and the Future of Metastatic Colorectal Cancer Treatment: Thomas Abrams, MD

Treatment options are limited for patients with metastatic colorectal cancer who have microsatellite-stable disease, which renders them ineligible for immune checkpoint inhibitor therapy. In a cohort of the COSMIC-021 trial, a team of researchers led by Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School, investigated the efficacy of cabozantinib plus atezolizumab for this patient population. Dr. Abrams recently presented the trial's results at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. In this interview, he discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.  

Continue reading

Addressing Knowledge Gaps in the Treatment of Metastatic Colorectal Cancer

An educational activity provided by i3 Health has revealed significant learning gains in the knowledge of novel treatment strategies for metastatic colorectal cancer (mCRC). The activity was presented virtually at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2020 and was made available as an enduring online activity. Colorectal cancer is the second leading cause of cancer death among women and men in the United States and is the third most diagnosed cancer worldwide. In the...

Continue reading

Guiding Colorectal Cancer Treatment Decisions by Using ctDNA With Jeanne Tie, MD, MBChB, FRACP

At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jeanne Tie spoke with Oncology Data Advisor to share more about her presentation regarding the clinical utility of circulating tumor DNA (ctDNA) analysis to guide treatment decision making for patients with colorectal cancer.  

Continue reading

Providing Proficiency for Personalized Care Plans for Metastatic Colorectal Cancer

An educational enduring online activity provided by i3 Health has demonstrated knowledge gains pertaining to up-to-date treatment and personalized health care plans for metastatic colorectal cancer (CRC). Recently the American Cancer Society estimated that CRC would see 151,030 new cases, with 52,580 of these diagnoses being fatal, this year alone, making CRC the third most commonly diagnosed cancer in the United States. If found early, CRC can be and is often cured, with a 5-year survival rate ...

Continue reading